UPSC Mains Answer: Bringing out the circumstances in 2005 which forced amendment to the section 3(d) in Indian Patent Law, 1970, discuss how it has been utilized by the Supreme Court in its judgement in rejecting Novratis' patent application for 'Glivec'. Discuss briefly the pros and cons of the dec

Difficulty Level: Hard

Sub-category: Indian Economy (Intellectual Property Rights and Patent Laws)

Introduction

The amendment to Section 3(d) of the Indian Patent Act, 1970, in 2005 was a pivotal moment in India’s intellectual property regime, aimed at preventing evergreening of patents and ensuring access to affordable medicines. This amendment was necessitated by global pharmaceutical pressures and India’s commitment to public health under the TRIPS Agreement.

Body

Circumstances in 2005

Post-2005, India aligned its patent laws with the TRIPS Agreement but introduced Section 3(d) to prohibit patents on new forms of known substances unless they demonstrated significantly enhanced efficacy. This was a response to concerns over multinational corporations extending patent monopolies through minor modifications, thereby delaying generic competition and inflating drug prices. The provision was particularly critical for life-saving drugs like antiretrovirals and cancer treatments.
Supreme Court’s Judgement (Novartis vs. Union of India, 2013): The Supreme Court upheld Section 3(d) in its landmark judgement rejecting Novartis’ patent application for Glivec (imatinib mesylate). The court ruled that the beta-crystalline form of imatinib did not exhibit significantly improved therapeutic efficacy over its earlier salt form, thus failing the test under Section 3(d). This decision reinforced India’s stance against evergreening and prioritized public health over corporate interests.

Pros and Cons

"Pros: The judgement ensured affordability of essential drugs, promoted generic competition, and set a global precedent for balancing patent rights with public health. Cons: Critics argue it may discourage pharmaceutical innovation in India and deter foreign investment in R&D. Additionally, the ambiguity in defining enhanced efficacy could lead to legal uncertainties.

Conclusion

The 2005 amendment and the Supreme Court’s ruling in the Novartis case exemplify India’s proactive approach to safeguarding public health while adhering to international obligations. The decision underscores the need for a balanced patent regime that fosters innovation without compromising accessibility to life-saving medicines.